FCGR3B and cancer: Recently, Lee et al. used an anti-CD16 monoclonal antibody (mAb) for potent activation of resting NK cells and irradiated autologous PBMC (upregulated NKG2D ligand and CD48) for providing a suitable environment (activating receptor-ligand interactions and soluble growth factors) instead of cancer cell-based feeder cells for large-scale expansion of highly purified cytotoxic NK cells (50).